Not all GLP-1 medications affect birth control the same way. Tirzepatide reduces oral contraceptive absorption. Semaglutide doesn't. And weight loss itself can make you more fertile than you were before.
The intersection of GLP-1 weight loss medications and reproductive health is more complicated than most patients realize. There's the direct pharmacokinetic interaction (does the drug change how well your birth control works?), the indirect fertility effect (does weight loss make pregnancy more likely?), and the pregnancy safety question (what happens if you conceive while taking the medication?).
Each one demands a clear answer. Here's what the evidence says.
Tirzepatide — sold as Mounjaro for type 2 diabetes and Zepbound for weight loss — has a documented interaction with oral hormonal contraceptives that semaglutide does not share.
In pharmacokinetic studies submitted to the FDA, tirzepatide reduced overall exposure (AUC) to oral contraceptive hormones by approximately 20%. The mechanism is delayed gastric emptying: tirzepatide slows stomach emptying more aggressively than semaglutide, which delays how quickly the hormones in your birth control pill reach the small intestine for absorption. Some of the hormones may be degraded before they're ever absorbed.
Eli Lilly's prescribing information for Mounjaro explicitly addresses this. The manufacturer recommends that patients taking oral hormonal contraceptives either use backup barrier contraception (condoms, diaphragm) for 4 weeks after initiating tirzepatide and for 4 weeks after each dose escalation, or switch to a non-oral contraceptive method.
The backup contraception requirement isn't one-and-done. Every time your tirzepatide dose increases — and the standard titration schedule involves 4–5 dose increases over 16–20 weeks — you need backup contraception for another 4 weeks. During a typical titration, this means backup methods are needed for essentially the entire ramp-up period.
Semaglutide (Ozempic, Wegovy, Rybelsus) studies have shown delayed peak absorption timing (Tmax) for oral contraceptives, but no clinically significant reduction in overall exposure. The prescribing information for semaglutide products does not recommend dose adjustment or backup contraception.
However, "no clinically significant interaction in studies" isn't the same as "no concern at all." All GLP-1 agonists slow gastric emptying to some degree, and individual variation in this effect is wide. Some women on semaglutide may experience more gastric emptying delay than the average study participant. If you're relying solely on an oral contraceptive and you notice significant GI side effects from semaglutide (prolonged nausea, vomiting within hours of taking your pill), talk to your prescriber about whether your contraception is still reliable.
Other GLP-1 agonists have their own nuances. Exenatide (Byetta, Bydureon) manufacturers recommend taking oral contraceptives at least 1 hour before the injection. Lixisenatide (Adlyxin) recommends taking oral birth control 1 hour before or 11 hours after the injection. For all others, no specific timing recommendations exist.
Regardless of which GLP-1 you take, non-oral contraceptive methods bypass the gastrointestinal tract entirely, making them immune to any absorption interaction:
Hormonal IUD (Mirena, Kyleena, Liletta): Delivers progestin directly to the uterus. 99%+ effective. Lasts 3–8 years depending on brand. No GI absorption involved.
Copper IUD (Paragard): Non-hormonal. 99%+ effective. Lasts up to 10 years. No drug interactions of any kind.
Implant (Nexplanon): Subdermal rod in the upper arm. 99%+ effective. Lasts 3–5 years. Systemic hormone delivery, no GI pathway.
Injectable (Depo-Provera): Intramuscular injection every 3 months. 94–99% effective. No oral absorption.
Patch (Xulane) and Ring (NuvaRing): Transdermal and vaginal delivery. While these are hormonal, they bypass the GI tract and are not expected to be affected by delayed gastric emptying.
This is the interaction that catches people off guard, because it's not a drug interaction at all — it's a biological consequence of the weight loss itself.
Excess weight, especially with insulin resistance, suppresses reproductive hormones. In women with PCOS (polycystic ovary syndrome) — a condition affecting 6–12% of women of reproductive age — insulin resistance directly impairs ovulation. Many women with PCOS have irregular or absent periods and assume they can't get pregnant.
When GLP-1 medications drive significant weight loss, insulin resistance improves. Ovulation can resume — sometimes within weeks of starting treatment. Women who haven't had regular periods in years may suddenly become fertile again. This isn't a side effect of the medication; it's a restoration of normal reproductive function that obesity had suppressed.
The term "Ozempic babies" emerged on social media as women reported unexpected pregnancies after starting GLP-1 therapy. While the plural anecdote isn't data, the biological mechanism is well-understood and predictable. If you're of reproductive age and starting GLP-1 therapy, assume your fertility may improve — even if you've been told conception would be difficult.
All GLP-1 medications are not recommended during pregnancy. Animal studies have shown adverse fetal outcomes including decreased growth, skeletal anomalies, and embryonic death. While limited human data on inadvertent first-trimester exposure has not shown clear harm, the FDA advises against use during pregnancy.
The FDA recommends stopping semaglutide at least 2 months before planned conception. Semaglutide has a long half-life (approximately 7 days), and it takes roughly 5 half-lives (5–7 weeks) to clear from the body. The 2-month window provides a safety margin.
For tirzepatide, the half-life is approximately 5 days, and similar guidance applies — discontinue well before attempting conception.
If you discover you're pregnant while taking a GLP-1 medication, contact your healthcare provider immediately. Discontinue the medication and discuss any necessary monitoring based on how far along the pregnancy is and when the last dose was taken.
GLP-1 medications are not recommended during breastfeeding. NIH LactMed data shows that injectable semaglutide was undetectable in breast milk samples, but the oral formulation contains an absorption enhancer (SNAC) that may enter breast milk. With insufficient safety data for nursing infants, the recommendation is to avoid all weight loss medications while breastfeeding. For more detail, see our guide on postpartum weight loss medication.
If you take tirzepatide (Mounjaro/Zepbound) and rely on the pill, patch it up with backup contraception or switch to a non-oral method. This isn't optional guidance — it's in the manufacturer's prescribing information.
If you take semaglutide (Ozempic/Wegovy), the direct birth control interaction is minimal, but don't ignore the fertility improvement from weight loss. If pregnancy isn't in your plans, make sure your contraception is reliable.
For any woman on GLP-1 therapy who wants bulletproof contraception, an IUD or implant eliminates the absorption question entirely.
The providers below include reproductive health screening in their weight loss consultations:
Comprehensive GLP-1 programs
Includes women's health screening and contraception counseling as part of the GLP-1 onboarding process.
Learn More →$300 per conversion — weight loss programs
Physician-led consultations that address medication interactions including contraceptive compatibility.
Get Started →Telehealth weight loss with full medical review
Thorough intake process that covers reproductive health, current medications, and family planning status.
Check Availability →